| 10.33 0.68 (7.05%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.56 | 1-year : | 15.98 |
| Resists | First : | 11.61 | Second : | 13.68 |
| Pivot price | 9.82 |
|||
| Supports | First : | 8.25 | Second : | 6.86 |
| MAs | MA(5) : | 9.25 |
MA(20) : | 10.34 |
| MA(100) : | 9.64 |
MA(250) : | 10.85 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.2 |
D(3) : | 18.4 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 37.11 | Low : | 3.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALGS ] has closed below upper band by 32.5%. Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.51 - 10.55 | 10.55 - 10.59 |
| Low: | 9.51 - 9.55 | 9.55 - 9.6 |
| Close: | 10.26 - 10.33 | 10.33 - 10.41 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Wed, 07 Jan 2026
UBS Initiates Coverage of Aligos Therapeutics (ALGS) with Buy Recommendation - Nasdaq
Wed, 07 Jan 2026
UBS Initiates Coverage on ALGS with a Buy Rating and $20 PT | AL - GuruFocus
Wed, 07 Jan 2026
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
Wed, 07 Jan 2026
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline - Investing.com
Fri, 26 Dec 2025
Aligos Therapeutics secures $105 million in private placement - MSN
Fri, 12 Dec 2025
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.14e+006 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 234 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.582e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 827.3 % |
| Return on Equity (ttm) | -54.8 % |
| Qtrly Rev. Growth | 2.65e+006 % |
| Gross Profit (p.s.) | -15.19 |
| Sales Per Share | -51.76 |
| EBITDA (p.s.) | -2.40146e+007 |
| Qtrly Earnings Growth | -13.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.2 |
| Price to Cash Flow | 2.42 |
| Dividend | 0 |
| Forward Dividend | 258240 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|